earnings
confidence high
sentiment positive
materiality 0.75
KalVista reports Q3 net loss $21.3M; sebetralstat phase 3 enrollment >50%, data H2 2023
KalVista Pharmaceuticals, Inc.
2023-Q3 EPS reported
-$2.58
- Net loss $21.3M ($0.75 per share), no revenue; R&D $20.1M, G&A $6.9M.
- Phase 3 KONFIDENT trial enrollment exceeds 50%; topline data expected H2 2023.
- FDA guidance: no efficacy trials required for ODT sNDA; PMDA guidance for Japan.
- Cash and securities $171.7M; $58M financing extends runway into 2025.
- Phase 2 sebetralstat data published in The Lancet; CFO Palleiko promoted to President.